Leukemia, Myeloid: all 2,432 studies
Page 17 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular ResponseCompletedNCT01933906Phase 1
- Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineCompletedNCT01926587Phase 1/2
- Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-LeukemiaCompletedNCT01914484Phase 1/2
- PH 2 ADI-PEG 20 Acute Myeloid LeukemiaCompletedNCT01910012Phase 2
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01904643Phase 1
- A Safety Study of SGN-CD33A in AML PatientsCompletedNCT01902329Phase 1
- Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In RemissionStatus unknownNCT01901666Phase 4
- Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia PatientsStatus unknownNCT01889407
- Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS TrialStatus unknownNCT01887561Phase 2
- Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT01872442Phase 2
- Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic LeukemiaApproved for marketingNCT01869803
- Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33Status unknownNCT01864902Phase 1/2
- TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet StudyCompletedNCT01860456
- Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ CellsCompletedNCT01856283Phase 2
- P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic MalignanciesCompletedNCT01854567Phase 3
- Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid LeukemiaCompletedNCT01843634Early Phase 1
- Sulindac for Patients With AMLWithdrawnNCT01843179Phase 2
- Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute LeukemiaCompletedNCT01842672Phase 1/2
- Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete RemissionCompletedNCT01842139Phase 1
- Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01839240Phase 1
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT01835288Phase 2
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01834248Phase 1
- Brentuximab Vedotin + Re-induction Chemotherapy for AMLCompletedNCT01830777Phase 1
- Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AMLCompletedNCT01830361Phase 2
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
- Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01822015Early Phase 1
- Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01820624Phase 1
- Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related AplasiaCompletedNCT01819792Phase 4
- Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid HemopathyCompletedNCT01819558Phase 1/2
- Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment IntoleranceCompletedNCT01819389Phase 3
- Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT01809392Phase 2/3
- Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationStatus unknownNCT01806116Phase 4
- Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid LeukemiaCompletedNCT01805843
- De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid LeukaemiaCompletedNCT01804985Phase 2
- Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseStatus unknownNCT01802450Phase 2
- Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid LeukemiaTerminatedNCT01801046Phase 1
- AR-42 and Decitabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01798901Phase 1
- Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic SyndromeTerminatedNCT01795924Phase 1/2
- Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell TransplantationCompletedNCT01795378Phase 1/2
- Mismatched Donor Cells to Treat Acute Myeloid LeukemiaStatus unknownNCT01793025Phase 1
- Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01787474Phase 1
- Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid LeukaemiaStatus unknownNCT01785953
- Alisertib for Acute Myeloid LeukemiaCompletedNCT01779843Phase 1
- A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous LeukemiaCompletedNCT01773408Phase 1
- Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)TerminatedNCT01770158
- CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01768897Phase 1
- Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaCompletedNCT01768689Not applicable
- the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia PatientStatus unknownNCT01766375Phase 3
- Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With DasatinibStatus unknownNCT01761890
- Chronic Myelod Leukemia Registry at Asan Medical CenterTerminatedNCT01761695
- Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01757639Phase 1
- A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01756118Phase 1
- Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+SuspendedNCT01755325Phase 3
- Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase InhibitorsStatus unknownNCT01752062
- Family-mismatched/Haploidentical Donors Versus Matched Unrelated DonorsCompletedNCT01751997Phase 2/3
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedNCT01751425Phase 1
- Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD ProphylaxisTerminatedNCT01749111Phase 3
- Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell TransplantActive, not recruitingNCT01744223Phase 1/2
- DC Vaccination for Postremission Therapy in AMLCompletedNCT01734304Phase 1/2
- Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid LeukemiaCompletedNCT01725204Phase 2
- Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)CompletedNCT01723657Phase 2
- Risk-adapted Therapy for Adult Acute Myeloid Leukemia.CompletedNCT01716793Phase 2
- Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus unknownNCT01716364Phase 1
- Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) PatientsCompletedNCT01702064Phase 1
- Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01701323Phase 1
- Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid LeukemiaCompletedNCT01700413Phase 2
- Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic PhaseCompletedNCT01699217
- Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AMLStatus unknownNCT01690065Phase 2
- Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in RemissionActive, not recruitingNCT01686334Phase 2
- AML-MDS Novel Prognostic Tests Clinical StudyCompletedNCT01685619
- Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCTCompletedNCT01683123
- Lenalidomide Plus Chemotherapy for AMLCompletedNCT01681537Phase 1
- An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer StudiesCompletedNCT01677780Phase 1
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous LeukemiaWithdrawnNCT01670084Phase 2
- Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER StudyCompletedNCT01657604Phase 3
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl PolymorphismsWithdrawnNCT01650467
- Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesTerminatedNCT01643603Phase 1
- Studying Biomarkers in Samples From Younger Patients With Acute Myeloid LeukemiaCompletedNCT01642121
- A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous LeukemiaCompletedNCT01641250Phase 1
- CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete RemissionWithdrawnNCT01639456Phase 2
- Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeTerminatedNCT01636609Phase 1
- A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous LeukemiaCompletedNCT01635296Phase 1
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia PatientsStatus unknownNCT01633099Phase 3
- A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in RemissionCompletedNCT01632852Phase 1
- Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT01629082Phase 1
- Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop TrialStatus unknownNCT01627132Phase 2
- WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity StudyCompletedNCT01621724Phase 1/2
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDSCompletedNCT01617226Phase 2
- Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML ConsolidationStatus unknownNCT01615757Phase 3
- A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) PatientsCompletedNCT01613976Phase 1
- Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic LeukemiaCompletedNCT01611116Phase 2
- Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell TransplantationCompletedNCT01608204
- Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid MalignanciesCompletedNCT01606579Phase 1/2
- Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKICompletedNCT01602952Phase 1/2
- Trial of Haploidentical Stem Cell Transplantation for Haematological CancersCompletedNCT01597219Phase 2